{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-039789","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.803223+00:00","generated_at":"2026-05-17T01:14:12.973740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Insmed Q3 revenue $142.3M (+52% YoY); net loss $370M; BRINSUPRI launch $28.1M; raises ARIKAYCE guidance","bullets":["ARIKAYCE global revenue $114.3M (+22% YoY); 2025 guidance raised to $420M-$430M.","BRINSUPRI (brensocatib) launched post-FDA approval, Q3 revenue $28.1M; EU positive CHMP opinion.","Net loss $370M ($1.75/shr) vs $220.5M ($1.27/shr) YoY, driven by higher R&D and SG&A for launch.","Cash and securities $1.7B; plans continued investment across pipeline (brensocatib, TPIP, gene therapy).","Upcoming catalysts: Ph2b BiRCh data (CRSsNP) by early Jan 2026; CEDAR (HS) data H1 2026; PALM-ILD start Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-039789","json":"https://secwatch.observer/filing/0001140361-25-039789.json","markdown":"https://secwatch.observer/filing/0001140361-25-039789.md","text":"https://secwatch.observer/filing/0001140361-25-039789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/0001140361-25-039789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125039789/ef20057768_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:14:12.973740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}